Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...
MedPage Today4d
The Basics of Multiple Myeloma
Multiple myeloma accounts for about 10% of all hematological ... Randomization to a quadruplet consisting of isatuximab (Sarclisa), an mAb targeting CD38, added to a standard triplet of bortezomib ...
The Pharma Letter10d
Sarclisa gains new approval in Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with ...
PharmiWeb10d
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...
KTLA10d
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma Paris, February 25, 2025. The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa ...
manilatimes10d
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...
London South East10d
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results ...